GlassScriptPhysician profile
Michael I Oliverio
NPI 1497781314
$4,856.75
in general payments reported to CMS, 2019-2025
32 companies · $909 in 2025
The $909 reported for 2025 was more than what 76% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $723 · 2020: $290 · 2021: $407 · 2022: $1,120 · 2023: $734 · 2024: $674 · 2025: $909.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,280 · Education: $36.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,279.87 |
| Education | $36.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $635.51 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Fresenius USA Marketing, INC. | $472.92 | 2019-2025 | Velphoro, Korsuva, Velphoro |
| Otsuka America Pharmaceutical, INC. | $370.00 | 2019-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $329.90 | 2019-2024 | Farxiga, Lokelma |
| Horizon Therapeutics Plc | $324.95 | 2019-2023 | Krystexxa |
| Vifor Pharma, INC. | $290.56 | 2019-2025 | Veltassa |
| Akebia Therapeutics INC | $276.45 | 2019-2025 | Vafseo |
| Calliditas Therapeutics US INC. | $241.29 | 2022-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $234.12 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $223.79 | 2021-2025 | Acthar, Terlivaz |
| Alexion Pharmaceuticals, INC. | $209.53 | 2019-2024 | Ultomiris |
| Travere Therapeutics, INC. | $166.05 | 2022-2024 | |
| Opko Pharmaceuticals, LLC | $130.52 | 2019-2023 | Rayaldee |
| Glaxosmithkline, LLC. | $126.37 | 2022-2025 | Benlysta, Jesduvroq |
| Aurinia Pharma U.S., INC. | $108.92 | 2021-2024 | Lupkynis |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $100.86 | 2025 | |
| Genzyme Corporation | $83.97 | 2019-2024 | |
| Apellis Pharmaceuticals, INC. | $70.32 | 2025 | Empaveli |
| Shire North American Group INC | $67.54 | 2019 | |
| Ardelyx, INC. | $62.41 | 2024-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.00 | 2023-2024 | Jardiance |
| Mallinckrodt Enterprises LLC | $41.75 | 2019 | |
| Kyowa Kirin, INC. | $41.55 | 2023-2025 | Crysvita |
| Novo Nordisk INC | $34.99 | 2023-2024 | Wegovy, Ozempic |
| Tersera Therapeutics LLC | $33.09 | 2022 | |
| Alnylam Pharmaceuticals INC. | $29.54 | 2022 | |
| Scpharmaceuticals INC. | $23.53 | 2025 | |
| Ani Pharmaceuticals, INC. | $23.37 | 2022 | |
| Lilly USA, LLC | $16.73 | 2025 | Jardiance |
| Ultragenyx Pharmaceutical INC. | $16.03 | 2020 | |
| Daiichi Sankyo INC. | $14.73 | 2019 | |
| Nuwellis, INC. | $12.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Oliverio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.